PB0744 - Examining the Effect of Chemotherapy on Platelet Count and Function in Women with Cancer

Monday, June 26, 2023

18:30 – 19:30 ET

Room: Exhibition

Presenting Author(s)

Shreya Anil Kumar (she/her/hers)

Undergraduate Student
Department of Biomedical and Molecular Sciences, School of Medicine, Queen's University, Kingston, Ontario, Canada
Kingston, Ontario, Canada

Co-Author(s)

YT

Yousra Tera

Postdoc Research fellow
Department of Biomedical and Molecular Sciences, School of Medicine, Queen's University, Kingston, Ontario, Canada
Mansoura, Ad Daqahliyah, Egypt
Mazen Assar, MD

Professor
School of Baccalaureate Nursing, St Lawrence College, Kingston, Ontario, Canada
Kingston, Ontario, Canada
YJ

Yoon Jin Suh

Research Assistant
School of Baccalaureate Nursing, St Lawrence College, Kingston, Ontario, Canada
Kingston, Ontario, Canada
MK

Maria Karizhenskaia

Research Assistant
Queen's University
Kingston, Ontario, Canada
KF

Karina Fainchtein

Undergraduate Student
Department of Biomedical and Molecular Sciences, School of Medicine, Queen's University, Kingston, Ontario, Canada
Kingston, Ontario, Canada
Maha Othman, MD PhD

Professor
Department of Biomedical and Molecular Sciences, School of Medicine, Queen's University, Kingston, Ontario, Canada,
Kingston, Ontario, Canada

Background: Evaluating platelet changes in patients receiving chemotherapy can provide a better understanding of platelet contribution to cancer progression and/or cancer-associated thrombosis. At present, there is little evidence on how chemotherapy affects platelet function, size, and count over time among various cancer patients.

Aims: We aim to examine changes in platelet count, mean platelet volume and whole blood platelet aggregation with chemotherapy cycles over time. We also aim to determine the association of the above changes, if any with cancer progression, bleeding tendency, or thrombotic events.

Methods: A single centre, prospective, longitudinal cohort study of adult cancer patients. Patients planning to receive the recommended chemotherapy treatments for gynecological and breast cancers were recruited. Blood samples were taken prior to chemotherapy and then again pre cycles 2 and 3. ADP-induced platelet aggregation was performed using Chrono-Log #592. Platelet count and MPV were assessed at the same frequent time points. Baseline demographics, menopausal status, BMI, Khorana score, VTE risk factors were recorded. Paired t-test was used to assess the effect of each chemo cycle compared to the basal level.

Results: A total of 32 patients have been recruited (17 breast, 10 endometrial, 5 ovarian). Aged 35-85 with 25 postmenopausal and 7 metastatic diseases (Table 1). Platelet count, size and aggregation were all within normal range, however there was a significant reduction in platelet count, size and aggregation after the first dose of chemotherapy (Figure 1) but no significant difference was not seen after the second dose of chemotherapy. No bleeding or thrombotic events were detected.

Conclusion(s): This data indicates platelets undergo changes after the first dose of chemotherapy. In order to observe the impact in each cancer type and cancer progression, long term follow up are required. These follow up studies can help understand how platelets can be targeted to improve outcomes and therapies in those patients.